Ken-ichi Inui

List of Publications by Year
in descending order

154	11,876	18482 62	29157 104
papers	citations	h-index	g-index

155	155	155	7749
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inhibitory effects of vandetanib on creatinine transport via renal organic cation transporter OCT2. European Journal of Pharmaceutical Sciences, 2021, 158, 105666.	4.0	3
2	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters. British Journal of Pharmacology, 2021, 178, S412-S513.	5.4	114
3	Disruption of Slc52a3 gene causes neonatal lethality with riboflavin deficiency in mice. Scientific Reports, 2016, 6, 27557.	3.3	20
4	Telaprevir-Induced Renal Adverse Events in Japanese Patients Reported in the PMDA Adverse Drug Reactions Reporting Database. Therapeutic Innovation and Regulatory Science, 2016, 50, 355-360.	1.6	2
5	Pharmacological and Toxicological Significance of the Organic Cation Transporters OCT and MATE: Drug Disposition, Interaction and Toxicity. , 2016, , 73-92.		2
6	Valacyclovir-Induced Acute Kidney Injury in Japanese Patients Based on the PMDA Adverse Drug Reactions Reporting Database. Therapeutic Innovation and Regulatory Science, 2015, 49, 81-85.	1.6	5
7	Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors. , 2015, 152, 125-134.		67
8	Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury. Cancer Chemotherapy and Pharmacology, 2015, 75, 1191-1197.	2.3	8
9	Evaluation of the Potency of Telaprevir and Its Metabolites as Inhibitors of Renal Organic Cation Transporters, a Potential Mechanism for the Elevation of Serum Creatinine. Drug Metabolism and Pharmacokinetics, 2014, 29, 266-271.	2.2	7
10	Developmental trajectory of intestinal <scp>MDR1/ABCB1</scp> mRNA expression in children. British Journal of Clinical Pharmacology, 2014, 77, 910-912.	2.4	19
11	The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma. Therapeutic Drug Monitoring, 2014, 36, 310-316.	2.0	35
12	Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins. Pharmaceutical Research, 2014, 31, 136-147.	3.5	51
13	Association between CYP3A5 Genotypes in Graft Liver and Increase in Tacrolimus Biotransformation from Steroid Treatment in Living-donor Liver Transplant Patients. Drug Metabolism and Pharmacokinetics, 2014, 29, 83-89.	2.2	19
14	Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer. Clinical Pharmacokinetics, 2013, 52, 593-609.	3.5	77
15	Multidrug and toxin extrusion family SLC47: Physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. Molecular Aspects of Medicine, 2013, 34, 661-668.	6.4	78
16	Novel riboflavin transporter family RFVT/SLC52: Identification, nomenclature, functional characterization and genetic diseases of RFVT/SLC52. Molecular Aspects of Medicine, 2013, 34, 693-701.	6.4	125
17	Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity. Biochemical Pharmacology, 2013, 85, 570-582.	4.4	30
18	Organic Cation Transporter OCTs (SLC22) and MATEs (SLC47) in the Human Kidney. AAPS Journal, 2013, 15, 581-588.	4.4	162

#	Article	IF	Citations
19	Precise comparison of protein localization among OCT, OAT, and MATE in human kidney. Journal of Pharmaceutical Sciences, 2013, 102, 3302-3308.	3.3	56
20	Developmental expression of renal organic anion transporters in rat kidney and its effect on renal secretion of phenolsulfonphthalein. American Journal of Physiology - Renal Physiology, 2012, 302, F1640-F1649.	2.7	18
21	Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics. Drug Metabolism and Pharmacokinetics, 2012, 27, 631-639.	2.2	82
22	Renal Tubular Secretion of Varenicline by Multidrug and Toxin Extrusion (MATE) Transporters. Drug Metabolism and Pharmacokinetics, 2012, 27, 563-569.	2.2	15
23	Involvement of autophagy in the pharmacological effects of the mTOR inhibitor everolimus in acute kidney injury. European Journal of Pharmacology, 2012, 696, 143-154.	3.5	61
24	Recent Advances in Structural Biology of Peptide Transporters. Current Topics in Membranes, 2012, 70, 257-274.	0.9	39
25	Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. European Journal of Clinical Pharmacology, 2012, 68, 259-266.	1.9	17
26	Renal Excretion of Vancomycin in Rats with Acute Renal Failure. Journal of Pharmacy and Pharmacology, 2011, 49, 154-157.	2.4	8
27	Tacrolimus Therapy as an Alternative to Thiopurines for Maintaining Remission in Patients With Refractory Ulcerative Colitis. Journal of Clinical Gastroenterology, 2011, 45, 526-530.	2.2	41
28	Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics. British Journal of Pharmacology, 2011, 164, 1817-1825.	5.4	155
29	Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Nonâ€“Small-Cell Lung Cancer With Pleural Effusion. Clinical Lung Cancer, 2011, 12, 307-312.	2.6	21
30	Organic cation transporter OCT/SLC22A and H+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochemical Pharmacology, 2011, 81, 563-568.	4.4	148
31	Human NPC1L1 Expression is Positively Regulated by PPARÎ±. Pharmaceutical Research, 2011, 28, 405-412.	3.5	33
32	Effects of Metabolic Acidosis on Expression Levels of Renal Drug Transporters. Pharmaceutical Research, 2011, 28, 1023-1030.	3.5	18
33	Maternal riboflavin deficiency, resulting in transient neonatal-onset glutaric aciduria Type 2, is caused by a microdeletion in the riboflavin transporter gene GPR172B. Human Mutation, 2011, 32, E1976-E1984.	2.5	96
34	Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenetics and Genomics, 2010, 20, 135-138.	1.5	48
35	Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 950-955.	1.1	125
36	A Case of Radiation Recall Pneumonitis Induced by Erlotinib, Which Can be Related to High Plasma Concentration. Journal of Thoracic Oncology, 2010, 5, 924-925.	1.1	30

#	Article	IF	Citations
37	The Globalization of JSSX DMPK Progress in Research. Drug Metabolism and Pharmacokinetics, 2010, 25, 319.	2.2	0
38	A Transient Increase of Calcineurin Phosphatase Activity in Living-Donor Kidney Transplant Recipients with Acute Rejection. Drug Metabolism and Pharmacokinetics, 2010, 25, 411-417.	2.2	19
39	Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis. Journal of Thoracic Oncology, 2010, 5, 601-605.	1.1	47
40	Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. International Journal of Clinical Oncology, 2010, 15, 512-514.	2.2	22
41	Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden sensorineural hearing loss: a prospective clinical trial. BMC Medicine, 2010, 8, 76.	5.5	96
42	mTOR inhibitor everolimus ameliorates progressive tubular dysfunction in chronic renal failure rats. Biochemical Pharmacology, 2010, 79, 67-76.	4.4	25
43	Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochemical Pharmacology, 2010, 80, 1762-1767.	4.4	180
44	Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 886-891.	2.8	25
45	ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Annals of Oncology, 2010, 21, 1382-1383.	1.2	51
46	Time-saving multiplex detection of single nucleotide polymorphisms by ultrasensitive DNA microarray. Journal of Biochemistry, 2010, 148, 557-563.	1.7	2
47	Reduced Renal Clearance of a Zwitterionic Substrate Cephalexin in Mate1-Deficient Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 651-656.	2.5	49
48	Identification and Comparative Functional Characterization of a New Human Riboflavin Transporter hRFT3 Expressed in the Brain. Journal of Nutrition, 2010, 140, 1220-1226.	2.9	121
49	Impact of Cyclin B2 and Cell division cycle 2 on tubular hyperplasia in progressive chronic renal failure rats. American Journal of Physiology - Renal Physiology, 2010, 298, F923-F934.	2.7	12
50	Hepatitis C Virus-related Cirrhosis is a Major Determinant of the Expression Levels of Hepatic Drug Transporters. Drug Metabolism and Pharmacokinetics, 2010, 25, 190-199.	2.2	66
51	Impact of IntestinalCYP2C19Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients. Drug Metabolism and Disposition, 2009, 37, 821-826.	3.3	38
52	Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 185-191.	2.5	170
53	Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. Journal of Human Genetics, 2009, 54, 40-46.	2.3	79
54	Targeted Disruption of the Multidrug and Toxin Extrusion 1 (Mate1) Gene in Mice Reduces Renal Secretion of Metformin. Molecular Pharmacology, 2009, 75, 1280-1286.	2.3	162

#	Article	IF	Citations
55	Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochemical Pharmacology, 2009, 77, 1429-1436.	4.4	48
56	Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochemical Pharmacology, 2009, 78, 1263-1271.	4.4	79
57	UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. International Journal of Clinical Oncology, 2009, 14, 136-142.	2.2	90
58	MDR1 Haplotypes Conferring an Increased Expression of Intestinal CYP3A4 Rather than MDR1 in Female Living-Donor Liver Transplant Patients. Pharmaceutical Research, 2009, 26, 1590-1595.	3.5	18
59	Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. Pharmacogenetics and Genomics, 2009, 19, 647-656.	1.5	20
60	A Retrospective Analysis of Vancomycin Pharmacokinetics in Japanese Cancer and Non-cancer Patients Based on Routine Trough Monitoring Data. Biological and Pharmaceutical Bulletin, 2009, 32, 99-104.	1.4	21
61	Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney. Journal of Human Genetics, 2008, 53, 607-614.	2.3	42
62	Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochemical Pharmacology, 2008, 75, 1689-1696.	4.4	131
63	Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochemical Pharmacology, 2008, 76, 894-903.	4.4	86
64	Relation between mRNA Expression Level of Multidrug Resistance 1/ABCB1 in Blood Cells and Required Level of Tacrolimus in Pediatric Living-Donor Liver Transplantation. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 610-616.	2.5	16
65	Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. American Journal of Physiology - Renal Physiology, 2008, 295, F247-F252.	2.7	34
66	Required Transient Dose Escalation of Tacrolimus in Living-Donor Liver Transplant Recipients with High Concentrations of a Minor Metabolite M-II in Bile. Drug Metabolism and Pharmacokinetics, 2008, 23, 313-317.	2.2	15
67	Effect of Intestinal and Hepatic First-pass Extraction on the Pharmacokinetics of Everolimus in Rats. Drug Metabolism and Pharmacokinetics, 2008, 23, 469-475.	2.2	11
68	Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1. American Journal of Physiology - Cell Physiology, 2008, 295, C632-C641.	4.6	126
69	Altered Pharmacokinetics of Cationic Drugs Caused by Down-Regulation of Renal Rat Organic Cation Transporter 2 (Slc22a2) and Rat Multidrug and Toxin Extrusion 1 (Slc47a1) in Ischemia/Reperfusion-Induced Acute Kidney Injury. Drug Metabolism and Disposition, 2008, 36, 649-654.	3.3	57
70	Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5. Drug Metabolism and Pharmacokinetics, 2008, 23, 134-138.	2.2	29
71	Identification of Essential Histidine and Cysteine Residues of the H+/Organic Cation Antiporter Multidrug and Toxin Extrusion (MATE). Molecular Pharmacology, 2007, 71, 1487-1493.	2.3	33
72	Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1. American Journal of Physiology - Renal Physiology, 2007, 293, F1564-F1570.	2.7	38

#	Article	IF	Citations
73	Clâ^'-dependent upregulation of human organic anion transporters: different effects on transport kinetics between hOAT1 and hOAT3. American Journal of Physiology - Renal Physiology, 2007, 293, F391-F397.	2.7	8
74	A Novel Approach to Therapeutic Angiogenesis for Patients With Critical Limb Ischemia by Sustained Release of Basic Fibroblast Growth Factor Using Biodegradable Gelatin Hydrogel An Initial Report of the Phase I-IIa Study. Circulation Journal, 2007, 71, 1181-1186.	1.6	121
75	Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. American Journal of Physiology - Renal Physiology, 2007, 292, F593-F598.	2.7	72
76	Gene expression and regulation of drug transporters in the intestine and kidney. Biochemical Pharmacology, 2007, 73, 440-449.	4.4	83
77	Pharmacokinetic significance of luminal multidrug and toxin extrusion 1 in chronic renal failure rats. Biochemical Pharmacology, 2007, 73, 1482-1490.	4.4	44
78	Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochemical Pharmacology, 2007, 74, 477-487.	4.4	217
79	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H+-organic cation antiporters. Biochemical Pharmacology, 2007, 74, 359-371.	4.4	369
80	Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenetics and Genomics, 2006, 16, 119-127.	1.5	125
81	Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clinical Pharmacology and Therapeutics, 2006, 79, 90-102.	4.7	50
82	Molecular Cloning, Functional Characterization and Tissue Distribution of Rat H+/Organic Cation Antiporter MATE1. Pharmaceutical Research, 2006, 23, 1696-1701.	3.5	120
83	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, 112, 184-198.		173
84	Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: Twice daily vs. once daily dosing. Liver Transplantation, 2006, 12, 292-300.	2.4	22
85	Interactions of Fluoroquinolone Antibacterials, DX-619 and Levofloxacin, with Creatinine Transport by Renal Organic Cation Transporter hOCT2. Drug Metabolism and Pharmacokinetics, 2006, 21, 432-436.	2.2	24
86	Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1â€“3 and Multidrug and Toxin Extrusion Family). Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 879-886.	2.5	300
87	Identification and Functional Characterization of a New Human Kidneyâ€“Specific H+/Organic Cation Antiporter, Kidney-Specific Multidrug and Toxin Extrusion 2. Journal of the American Society of Nephrology: JASN, 2006, 17, 2127-2135.	6.1	348
88	Transport Characteristics of a Novel Peptide Transporter 1 Substrate, Antihypotensive Drug Midodrine, and Its Amino Acid Derivatives. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 455-460.	2.5	62
89	Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. Clinical Pharmacology and Therapeutics, 2005, 78, 168-181.	4.7	75
90	Computational modelling of H+-coupled peptide transport via human PEPT1. Journal of Physiology, 2005, 565, 429-439.	2.9	30

#	Article	IF	Citations
91	Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochemical Pharmacology, 2005, 70, 1104-1113.	4.4	114
92	Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochemical Pharmacology, 2005, 70, 1823-1831.	4.4	152
93	Expression profiles of various transporters for oligopeptides, amino acids and organic ions along the human digestive tract. Biochemical Pharmacology, 2005, 70, 1756-1763.	4.4	78
94	Metformin Transport by Renal Basolateral Organic Cation Transporter hOCT2. Pharmaceutical Research, 2005, 22, 255-259.	3.5	156
95	Pharmacokinetic Significance of Renal OAT3 (SLC22A8) for Anionic Drug Elimination in Patients with Mesangial Proliferative Glomerulonephritis. Pharmaceutical Research, 2005, 22, 2016-2022.	3.5	35
96	Metformin is a Superior Substrate for Renal Organic Cation Transporter OCT2 rather than Hepatic OCT1. Drug Metabolism and Pharmacokinetics, 2005, 20, 379-386.	2.2	313
97	Distinct Inhibitory Effects of Tacrolimus and Cyclosporin A on Calcineurin Phosphatase Activity. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 816-825.	2.5	38
98	Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3569-3574.	7.1	261
99	Lansoprazoleâ€”Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism. Annals of Pharmacotherapy, 2004, 38, 791-794.	1.9	36
100	Methotrexate-Loxoprofen Interaction: Involvement of Human Organic Anion Transporters hOAT1 and hOAT3. Drug Metabolism and Pharmacokinetics, 2004, 19, 369-374.	2.2	86
101	Gene expression variance based on random sequencing in rat remnant kidney. Kidney International, 2004, 66, 29-45.	5.2	15
102	Expression Levels of Renal Organic Anion Transporters (OATs) and Their Correlation with Anionic Drug Excretion in Patients with Renal Diseases. Pharmaceutical Research, 2004, 21, 61-67.	3.5	95
103	Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney. Pharmaceutical Research, 2004, 21, 976-981.	3.5	180
104	Common single nucleotide polymorphisms of the MDR1 gene have no influence on its mRNA expression level of normal kidney cortex and renal cell carcinoma in Japanese nephrectomized patients. Journal of Human Genetics, 2004, 49, 40-45.	2.3	28
105	Genetic variant Arg57His in human H+/peptide cotransporter 2 causes a complete loss of transport function. Biochemical and Biophysical Research Communications, 2004, 316, 416-420.	2.1	44
106	(Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) Peptide Transporters: Structure, Function, Regulation and Application for Drug Delivery. Current Drug Metabolism, 2004, 5, 85-94.	1.2	167
107	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics and Genomics, 2004, 14, 471-478.	5.7	182
108	Forecasting of Blood Tacrolimus Concentrations Based on the Bayesian Method in Adult Patients Receiving Living-Donor Liver Transplantation. Clinical Pharmacokinetics, 2003, 42, 1161-1178.	3.5	38

#	Article	IF	Citations
109	Distinct transport activity of tetraethylammonium from l-carnitine in rat renal brush-border membranes. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1609, 218-224.	2.6	7
110	cDNA Cloning, Functional Characterization, and Tissue Distribution of an Alternatively Spliced Variant of Organic Cation Transporter hOCT2 Predominantly Expressed in the Human Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 1703-1710.	6.1	114
111	C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics and Genomics, 2002, 12, 451-457.	5.7	186
112	Rat Renal Organic Anion Transporter rOAT1 Mediates Transport of Urinary-Excreted Cephalosporins, but not of Biliary-Excreted Cefoperazone. Drug Metabolism and Pharmacokinetics, 2002, 17, 125-129.	2.2	23
113	Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney International, 2002, 62, 514-524.	5.2	132
114	Gene Expression Levels and Immunolocalization of Organic Ion Transporters in the Human Kidney. Journal of the American Society of Nephrology: JASN, 2002, 13, 866-874.	6.1	450
115	Interaction of Azole Antifungal Agents with Human P-glycoprotein Expressed in a Kidney Epithelial Cell Line, LLC-PK1.. Drug Metabolism and Pharmacokinetics, 2001, 16, 5-11.	0.0	1
116	Independent organic cation transport activity of Na⁺-<scp>l</scp>-carnitine cotransport system in LLC-PK₁ cells. American Journal of Physiology - Renal Physiology, 2001, 281, F273-F279.	2.7	4
117	Upregulation of H⁺-peptide cotransporter PEPT2 in rat remnant kidney. American Journal of Physiology - Renal Physiology, 2001, 281, F1109-F1116.	2.7	39
118	Distinct transport characteristics of basolateral peptide transporters between MDCK and Caco-2 cells. Pflugers Archiv European Journal of Physiology, 2001, 443, 31-37.	2.8	15
119	Role of kidney-specific organic anion transporters in the urinary excretion of methotrexate. Kidney International, 2001, 60, 1058-1068.	5.2	40
120	Effects of tacrolimus and cyclosporin A on peptide transporter PEPT1 in Caco-2 cells. Pharmaceutical Research, 2001, 18, 713-717.	3.5	7
121	Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clinical Pharmacology and Therapeutics, 2001, 69, 308-316.	4.7	120
122	Cellular and molecular aspects of drug transport in the kidney. Kidney International, 2000, 58, 944-958.	5.2	404
123	Kinetic analysis of p-aminohippurate transport in the OK kidney epithelial cell line. Pharmaceutical Research, 2000, 17, 1155-1157.	3.5	4
124	Differential localization of organic cation transporters rOCT1 and rOCT2 in the basolateral membrane of rat kidney proximal tubules. Histochemistry and Cell Biology, 2000, 114, 175-180.	1.7	74
125	Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2. Pflugers Archiv European Journal of Physiology, 2000, 440, 679-684.	2.8	91
126	Diphenhydramine transport by pH-dependent tertiary amine transport system in Caco-2 cells. American Journal of Physiology - Renal Physiology, 2000, 278, G563-G569.	3.4	29

#	Article	IF	Citations
127	Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Letters, 2000, 473, 173-176.	2.8	125
128	Effects of glibenclamide on glycylsarcosine transport by the rat peptide transporters PEPT1 and PEPT2. British Journal of Pharmacology, 1999, 128, 1159-1164.	5.4	29
129	Peptide transporter in the rat small intestine: ultrastructural localization and the effect of starvation and administration of amino acids. The Histochemical Journal, 1999, 31, 169-174.	0.6	103
130	Distribution characteristics of levofloxacin and grepafloxacin in rat kidney. Pharmaceutical Research, 1999, 16, 534-539.	3.5	37
131	Effects of arbekacin and vancomycin on release of lactate dehydrogenase and fragmentation of DNA in LLC-PK1 kidney epithelial cells. Pharmaceutical Research, 1999, 16, 1132-1135.	3.5	3
132	Functional analysis of rat renal organic anion transporter OATâ€K1: bidirectional methotrexate transport in apical membrane. FEBS Letters, 1999, 459, 128-132.	2.8	38
133	Gender differences in expression of organic cation transporter OCT2 in rat kidney. FEBS Letters, 1999, 461, 339-342.	2.8	148
134	Cisplatin-induced toxicity in LLC-PK1 kidney epithelial cells: role of basolateral membrane transport. Toxicology Letters, 1999, 106, 229-235.	0.8	28
135	Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein*. Clinical Pharmacology and Therapeutics, 1998, 64, 123-128.	4.7	201
136	Effect of neutral endopeptidase inhibition on the natriuresis and renal clearance of atrial natriuretic peptide in perfused rat kidney. Pharmaceutical Research, 1998, 15, 1499-1502.	3.5	1
137	Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. Pharmaceutical Research, 1998, 15, 1609-1613.	3.5	70
138	Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharmaceutical Research, 1998, 15, 734-738.	3.5	26
139	Cellular and molecular mechanisms of renal tubular secretion of organic anions and cations. Clinical and Experimental Nephrology, 1998, 2, 100-108.	1.6	41
140	Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS Letters, 1998, 438, 321-324.	2.8	124
141	mRNA distribution and membrane localization of the OATâ€K1 organic anion transporter in rat renal tubules. FEBS Letters, 1997, 407, 127-131.	2.8	81
142	Evaluation of renal tubular secretion and reabsorption of levofloxacin in rats. Pharmaceutical Research, 1997, 14, 508-511.	3.5	21
143	Kinetic analysis of tetraethylammonium transport in the kidney epithelial cell line, LLC-PK1. Pharmaceutical Research, 1997, 14, 1236-1240.	3.5	18
144	Identification of the histidine residues involved in substrate recognition by a rat H+/peptide cotransporter, PEPT1. FEBS Letters, 1996, 394, 196-200.	2.8	81

#	Article	IF	Citations
145	Immuno-Localization of H+/Peptide Cotransporter in Rat Digestive Tract. Biochemical and Biophysical Research Communications, 1996, 220, 848-852.	2.1	213
146	cDNA Cloning and Functional Expression of a Novel Rat Kidney Organic Cation Transporter, OCT2. Biochemical and Biophysical Research Communications, 1996, 224, 500-507.	2.1	335
147	Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. Pharmaceutical Research, 1996, 13, 1073-1077.	3.5	33
148	Modulation of organic cation transport and lipid fluidity by benzyl alcohol in rat renal brush-border membranes. Pharmaceutical Research, 1996, 13, 1069-1072.	3.5	2
149	Transport characteristics of ceftibuten, a new cephaloporin antibiotic, via the apical H+/dipeptide cotransport system in human intestinal cell line Caco-2: regulation by cell growth. Pharmaceutical Research, 1995, 12, 1483-1487.	3.5	17
150	Decreased cellular toxicity of neomycin in a clonal cell line isolated from LLC-PK1. Pharmaceutical Research, 1993, 10, 573-576.	3.5	4
151	Analysis of Regulatory Mechanisms for Tubular Secretion of Organic Cations by Cultured Renal Cells. Drug Metabolism and Pharmacokinetics, 1993, 8, 719-722.	0.0	0
152	Decreased transport of p-aminohippurate in renal basolateral membranes isolated from rats with acute renal failure. Pharmaceutical Research, 1989, 06, 954-957.	3.5	9
153	Carrier-mediated transport systems of tetraethylammonium in rat renal brush-border and basolateral membrane vesicles. Biochimica Et Biophysica Acta - Biomembranes, 1984, 773, 113-124.	2.6	152
154	Carrier-mediated transport of amino-cephalosporins by brush border membrane vesicles isolated from rat kidney cortex. Biochemical Pharmacology, 1983, 32, 621-626.	4.4	42